Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of the effect of prospective biomarker testing on progression-free survival in diffuse large B-cell lymphoma.
Szafer-Glusman E, Liu J, Sinha A, Peale FV Jr, Ray J, Horn C, Oestergaard MZ, Kornacker M, Sehn LH, Vitolo U, Knapp A, Venstrom J, Byrtek M, Punnoose E. Szafer-Glusman E, et al. Among authors: kornacker m. Leuk Lymphoma. 2021 Apr;62(4):999-1002. doi: 10.1080/10428194.2020.1849674. Epub 2020 Dec 16. Leuk Lymphoma. 2021. PMID: 33325309 No abstract available.
Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial.
Zelenetz AD, Salles G, Mason KD, Casulo C, Le Gouill S, Sehn LH, Tilly H, Cartron G, Chamuleau MED, Goy A, Tam CS, Lugtenburg PJ, Petrich AM, Sinha A, Samineni D, Herter S, Ingalla E, Szafer-Glusman E, Klein C, Sampath D, Kornacker M, Mobasher M, Morschhauser F. Zelenetz AD, et al. Among authors: kornacker m. Blood. 2019 May 2;133(18):1964-1976. doi: 10.1182/blood-2018-11-880526. Epub 2019 Mar 8. Blood. 2019. PMID: 30850381 Free PMC article. Clinical Trial.
Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma.
Zinzani PL, Flinn IW, Yuen SLS, Topp MS, Rusconi C, Fleury I, Le Dû K, Arthur C, Pro B, Gritti G, Crump M, Petrich A, Samineni D, Sinha A, Punnoose EA, Szafer-Glusman E, Spielewoy N, Mobasher M, Humphrey K, Kornacker M, Hiddemann W. Zinzani PL, et al. Among authors: kornacker m. Blood. 2020 Dec 3;136(23):2628-2637. doi: 10.1182/blood.2020005588. Blood. 2020. PMID: 32785666 Free PMC article. Clinical Trial.
Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma.
Dickinson M, Briones J, Herrera AF, González-Barca E, Ghosh N, Cordoba R, Rutherford SC, Bournazou E, Labriola-Tompkins E, Franjkovic I, Chesne E, Brouwer-Visser J, Lechner K, Brennan B, Nüesch E, DeMario M, Rüttinger D, Kornacker M, Hutchings M. Dickinson M, et al. Among authors: kornacker m. Blood Adv. 2021 Nov 23;5(22):4762-4770. doi: 10.1182/bloodadvances.2021004619. Blood Adv. 2021. PMID: 34581757 Free PMC article. Clinical Trial.
A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma.
Shapiro GI, LoRusso P, Dowlati A, T Do K, Jacobson CA, Vaishampayan U, Weise A, Caimi PF, Eder JP, French CA, Labriola-Tompkins E, Boisserie F, Pierceall WE, Zhi J, Passe S, DeMario M, Kornacker M, Armand P. Shapiro GI, et al. Among authors: kornacker m. Br J Cancer. 2021 Feb;124(4):744-753. doi: 10.1038/s41416-020-01180-1. Epub 2020 Dec 14. Br J Cancer. 2021. PMID: 33311588 Free PMC article. Clinical Trial.
A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma.
Ramasamy K, Nooka A, Quach H, Htut M, Popat R, Liedtke M, Tuchman SA, Laubach J, Gasparetto C, Chanan-Khan A, Hertzberg M, deMario M, Nueesch E, Chesne E, Franjkovic I, Lechner K, Kornacker M, Cho HJ. Ramasamy K, et al. Among authors: kornacker m. Blood Cancer J. 2021 Sep 3;11(9):149. doi: 10.1038/s41408-021-00545-w. Blood Cancer J. 2021. PMID: 34480019 Free PMC article. Clinical Trial. No abstract available.
Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies.
Bahleda R, Grilley-Olson JE, Govindan R, Barlesi F, Greillier L, Perol M, Ray-Coquard I, Strumberg D, Schultheis B, Dy GK, Zalcman G, Weiss GJ, Walter AO, Kornacker M, Rajagopalan P, Henderson D, Nogai H, Ocker M, Soria JC. Bahleda R, et al. Among authors: kornacker m. Br J Cancer. 2017 Jun 6;116(12):1505-1512. doi: 10.1038/bjc.2017.92. Epub 2017 May 2. Br J Cancer. 2017. PMID: 28463960 Free PMC article. Clinical Trial.
63 results